Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Search
Drug Profile

Prexigebersen - Bio-Path Holdings

Alternative Names: BP 100-1-01; BP-100-1.01; BP-1001; BP1001-A; L-Grb-2; L-Grb-2 antisense; Liposomal Grb2 antisense oligonucleotide; Prexigebersen-A

Latest Information Update: 02 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Texas M. D. Anderson Cancer Center
  • Developer Bio-Path Holdings; University of Texas M. D. Anderson Cancer Center
  • Class Antineoplastics; Antisense oligonucleotides; Obesity therapies
  • Mechanism of Action Gene silencing; GRB2 adaptor protein expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chronic myeloid leukaemia; Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Myelodysplastic syndromes
  • Phase I/II Chronic myeloid leukaemia
  • Phase I Solid tumours
  • Preclinical Obesity
  • No development reported Breast cancer; Colorectal cancer; Head and neck cancer; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Thyroid cancer

Most Recent Events

  • 18 Mar 2025 Pharmacodynamics data from a preclinical study in Obesity released by Bio-Path Holdings
  • 18 Mar 2025 Bio-Path Holdings plans a phase I trial for Obesity in 2025
  • 20 Feb 2025 Prexigebersen is still in phase-I development in Solid-tumours (Combination therapy, Monotherapy, Late-stage disease, Recurrent) in USA (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days

Market Movers of 2025 Webinar

This session is built around insights from our in-depth analysis of drug candidates and market shifts expected to shape the pharmaceutical landscape in 2025. We’ll explore two transformative categories (1) Groundbreaking Drug Launches and (2) Patent Expiration & Market Impact. This webinar will also focus on pivotal clinical trials and regulatory milestones, showcasing how data-driven strategies are shaping the development and approval of these market movers.

Register now